Gene-based vaccines: recent technical and clinical advances

被引:123
作者
Ulmer, Jeffrey B.
Wahren, Britta
Liu, Margaret A.
机构
[1] Transgene SA, F-67082 Strasbourg, France
[2] Karolinska Inst, S-17182 Solna, Sweden
[3] Swedish Inst Infect Dis Control, S-17182 Solna, Sweden
[4] Chiron Vaccines, Emeryville, CA 94608 USA
关键词
D O I
10.1016/j.molmed.2006.03.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA vaccines have been widely used in efforts to develop vaccines against various pathogens as well as for cancer, autoimmune diseases and allergy. DNA vaccines offer broad efficacy (particularly for their ability to generate both cellular and humoral immunity), ease of construction and manufacture and the potential for world-wide usage even in low-resource settings. However, despite their successful application in many preclinical disease models, their potency in human clinical trials has been insufficient to provide protective immunity. Nevertheless, two DNA vaccines were recently licensed for use in animals (horse and fish), underscoring the potential of this technology. Here, we describe recent advances in increasing the potency of these vaccine, in understanding their immunological mechanisms, and in their applications and efficacy in clinical trials so far.
引用
收藏
页码:216 / 222
页数:7
相关论文
共 48 条
[1]   A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression [J].
Bins, AD ;
Jorritsma, A ;
Wolkers, MC ;
Hung, CF ;
Wu, TC ;
Schumacher, TNM ;
Haanen, JBAG .
NATURE MEDICINE, 2005, 11 (08) :899-904
[2]   Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery [J].
Bråve, A ;
Ljungberg, K ;
Boberg, A ;
Rollman, E ;
Isaguliants, M ;
Lundgren, B ;
Blomberg, P ;
Hinkula, J ;
Wahren, B .
MOLECULAR THERAPY, 2005, 12 (06) :1197-1205
[3]   Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen [J].
Buchan, S ;
Gronevik, E ;
Mathiesen, I ;
King, CA ;
Stevenson, FK ;
Rice, J .
JOURNAL OF IMMUNOLOGY, 2005, 174 (10) :6292-6298
[4]   Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug [J].
Charo, J ;
Lindencrona, JA ;
Carlson, LM ;
Hinkula, J ;
Kiessling, R .
JOURNAL OF VIROLOGY, 2004, 78 (20) :11321-11326
[5]   Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis [J].
Chattergoon, MA ;
Kim, JJ ;
Yang, JS ;
Robinson, TM ;
Lee, DJ ;
Dentchev, T ;
Wilson, DM ;
Ayyavoo, V ;
Weiner, DB .
NATURE BIOTECHNOLOGY, 2000, 18 (09) :974-979
[6]   Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors [J].
Coban, C ;
Ishii, KJ ;
Gursel, M ;
Klinman, DM ;
Kumar, N .
JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 78 (03) :647-655
[7]   Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus [J].
Dale, CJ ;
De Rose, R ;
Stratov, I ;
Chea, S ;
Montefiori, DC ;
Thomson, S ;
Ramshaw, IA ;
Coupar, BEH ;
Boyle, DB ;
Law, M ;
Kent, SJ .
JOURNAL OF VIROLOGY, 2004, 78 (24) :13819-13828
[8]   Unexpectedly, induction of cytotoxic T lymphocytes enhances the humoral response after DNA immunization [J].
Dyer, CM ;
Zhan, YF ;
Brady, JL ;
Carbone, FR ;
Smyth, MJ ;
Lew, AM .
BLOOD, 2004, 103 (08) :3073-3075
[9]   Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein [J].
Epstein, SL ;
Kong, WP ;
Misplon, JA ;
Lo, CY ;
Tumpey, TM ;
Xu, L ;
Nabel, GJ .
VACCINE, 2005, 23 (46-47) :5404-5410
[10]   A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and a antigens improves protection against tuberculosis in mice [J].
Ferraz, JC ;
Stavropoulos, E ;
Yang, M ;
Coade, S ;
Espitia, C ;
Lowrie, DB ;
Colston, MJ ;
Tascon, RE .
INFECTION AND IMMUNITY, 2004, 72 (12) :6945-6950